<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35032278</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7365</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Metabolic brain disease</Title>
          <ISOAbbreviation>Metab Brain Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A kinetic scheme to examine the role of glial cells in the pathogenesis of Alzheimer's disease.</ArticleTitle>
        <Pagination>
          <StartPage>801</StartPage>
          <EndPage>805</EndPage>
          <MedlinePgn>801-805</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11011-022-00902-z</ELocationID>
        <Abstract>
          <AbstractText>Alzheimer's disease (AD) is a complex neurodegenerative disorder that leads to severe impairments in cognitive functions including memory and learning. An improved kinetic model is proposed here to understand the pathogenesis of AD in particular the role of glial cells in the presence of amyloid plaques and neurofibrillary tangles (NFTs). The kinetic model describes the production of activated microglia and astroglia. It involves two rate equations and incorporates the dual role of these glial cells which can function as neuroprotective and as neurotoxic cells. Examination of the steady state solutions of the model predicts an increase in population of these glial cells as (AD) progresses, and that this continues to increase linearly even after the amyloid population has reached a plateau.This is in agreement with experimental data. Limiting AD to the effect of amyloid peptides alone is incorrect and the role of neurofibrillary tangles, clearance rate of dead neurons and neuroinflammation from glial cells are vital and must be included in understanding the pathogenesis of AD. The study shows that increasing the clearance of dead neurons and use of any method to deactivate the glial cells will diminish the progression of AD.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thuraisingham</LastName>
            <ForeName>R A</ForeName>
            <Initials>RA</Initials>
            <Identifier Source="ORCID">0000-0002-9373-565X</Identifier>
            <AffiliationInfo>
              <Affiliation>, 1A, Russell Street, Eastwood, NSW, 2122, Australia. ranjit@optusnet.com.au.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Metab Brain Dis</MedlineTA>
        <NlmUniqueID>8610370</NlmUniqueID>
        <ISSNLinking>0885-7490</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimers disease</Keyword>
        <Keyword MajorTopicYN="Y">Astroglia</Keyword>
        <Keyword MajorTopicYN="Y">Kinetic model</Keyword>
        <Keyword MajorTopicYN="Y">Microglia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35032278</ArticleId>
        <ArticleId IdType="doi">10.1007/s11011-022-00902-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s11011-022-00902-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abiega O, Beccari S, Diaz-Aparicio I, Nadjar A, Layé S et al (2016) Neuronal hyperactivity disturbs ATP microgradients, impairs microglial motility, and reduces phagocytic receptor expression triggering apoptosis/microglial phagocytosis uncoupling. PLOS Biol 14(5):e1002466</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.1002466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abramov AY, Duchen MR (2005) The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos Trans R Soc Lond B Biol Sci 360:2309–2314</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1098/rstb.2005.1766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Caluwé J, Dupont G (2013) The progression towards Alzheimer’s disease described as a bistable switch arising from the positive loop between amyloids and Ca2+. J Theoret Biol 331:12–18</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtbi.2013.04.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dossi E, Vasile F, Rouach N (2018) Human astrocytes in the diseased brain. Brain Res Bull 136:139–156</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2017.02.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escartin C, Galea E, Lakatos A et al (2021) Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 24:312–325</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fakhoury M (2018) Microglia and astrocytes in Alzheimer’s disease: implications for therapy. Curr Neuropharmacol 16(5):508–518</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1570159X15666170720095240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grathwohl SA, Kälin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S et al (2009) Formation and maintenance of Alzheimer’s disease β-amyloid plaques in the absence of microglia. Nat Neurosci 12:1361–1363</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.2432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 45:583–595</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2004.03.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YS, Jung HM, Yoo B (2018) Exploring glia to better understand Alzheimer’s disease. Anim Cells Syst (Seoul) 22(4):213–218</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19768354.2018.1508498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li K, Li J, Zheng J, Qin S (2019) Reactive astrocytes in neurodegenerative diseases. Aging Dis 10(3):664–675</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14336/AD.2018.0720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G (2017) Apoe4 accelerates early seeding of amyloid pathology. Neuron 96:1024–1032</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2017.11.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuno T, Doi Y, Mizoguchi H, Jin S, Noda M, Sonobe Y, Takeuchi H, Suzumura A (2011) Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol 179:2016–2027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2011.06.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann H, Kotter MR, Franklin RJM (2008) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132:288–295</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Overmyer M, Helisalmi S, Soininen H, Laakso M, RiekkinenSr P, Alafuzoff I (1999) Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathol 97:383–392</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004010051002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT (2011) Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol 179:1373–1384</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT (2013) A phenotypic change but not proliferation underlies glial responses in Alzheimer disease, majority of the glia responses observed in the AD brain. Am J Pathol 182(6):2332–2344</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2013.02.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheffield LG, Marquis JG, Berman NE (2000) Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett 285:165–168</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3940(00)01037-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng JG, Mrak RE, Griffin WS (1997) Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1α <sup>+</sup> microglia and S100β <sup>+</sup> astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 56:285–290</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005072-199703000-00007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thurasisingham RA (2018) Pathogenesis of Alzheimer’s disease examined using a modified Puri-Li model that incorporates calcium ion homeostasis. J Mol Neuroscience 65(2):119–126</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-018-1080-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thuraisingham RA (2017) Examining the role of microglia and astroglia during the pathogenesis of Alzheimer’s disease via the Puri-Li model. J Mol Neuroscience 62(3–4):363–387</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-017-0946-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang WY, Tan MS, Yu JT, Tan L (2015) Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 3(10):136–150</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26207229</ArticleId>
            <ArticleId IdType="pmc">4486922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003) Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat Med 9:453–457</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Wang W (2020) Mathematical analysis of stochastic model for Alzheimer’s disease. Commun Nonlinear Sci Numer Simulat 89:105347</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cnsns.2020.105347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madan A, Obetkova D, Bugos O, Novak M (2012) Who fans the flames of Alzheimers’s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation 9:47</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-9-47</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
